Electrochemotherapy for the management of melanoma skin metastasis: A review of the literature and possible combinations with immunotherapy

Archives of Dermatological Research

Volumn 306, Issue 6, 2014, Pages 521-526

  Queirolo, Paola ^a   Marincola, Francesco ^b   Spagnolo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Electrochemotherapy; Immunotherapy; Ipilimumab; Melanoma; Skin metastasis

Indexed keywords

BLEOMYCIN; CISPLATIN; IPILIMUMAB; ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; ELECTROCHEMOTHERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MELANOMA; META ANALYSIS (TOPIC); MUSCLE SPASM; MYOCLONUS; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; REGIONAL PERFUSION; REVIEW; SKIN METASTASIS; SYSTEMATIC REVIEW (TOPIC); TRANSLATIONAL RESEARCH; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; VISCERAL METASTASIS; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES; SECONDARY; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ELECTROCHEMOTHERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84904748751     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-014-1462-x     Document Type: Review

References (55)

1. Andersen MH, Gehl J, Reker S et al (2003) Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13(6):449-459 (Pubitemid 38156137)
2. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206
3. Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15(8):2195-2205
4. Byrne CM, Thompson JF, Johnston H et al (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15(1):45-51 (Pubitemid 40354473)
5. Campana LG, Valpione S, Mocellin S et al (2012) Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 99(6):821-830
6. Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26(36):5896-5903
7. Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB (2003) Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol Immunother 52(3):162-170 (Pubitemid 36384716)
8. Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB (2001) Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol 166(11):6491-6499 (Pubitemid 32467186)
9. Fisher R, Larkin J (2012) Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 4:243-252
10. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 10(3):115-121 (Pubitemid 351517524)
11. Gerlini G, Di Gennaro P, Borgognoni L (2012) Enhancing antimelanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1(9):1655-1657
12. Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L (2013) Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 30(1):37-45
13. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132(11):1353-1357 (Pubitemid 26386624)
14. Gyorki DE, Yuan J, Mu Z et al (2013) Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 20(9):3106-3111
15. Heller R, Jaroszeski MJ, Reintgen DS et al (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83(1):148-157 (Pubitemid 28299641)
16. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R (2000) In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10(6):577-583 (Pubitemid 32011981)
17. Hodi FS, O'Day SJ, McDermott DF (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723
18. Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19(5):275-282
19. Kis E, Oláh J, Ócsai H, Baltas E, Gyulai R, Kemény L, Horvath AR (2011) Electrochemotherapy of cutaneous metastases of melanoma - a case series study and systematic review of the evidence. Dermatol Surg 37(6):816-824
20. Kroon BB, Noorda EM, Vrouenraets BC, van Slooten GW, Nieweg OE (2008) Isolated limb perfusion for melanoma. Surg Oncol Clin N Am 17(4):785-794 (viii-ix)
21. Kroon HM, Thompson JF (2009) Isolated limb infusion: a review. J Surg Oncol 100(2):169-177
22. Maio M (2012) Melanoma as a model tumour for immunooncology. Ann Oncol 23(Suppl 8):viii10-viii14. doi:10.1093/annonc/mds257
23. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39(1):4-16
24. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, Jarm T (2013) Tumor size and effectiveness of electrochemotherapy. Radiol Oncol 47(1):32-41
25. Marty MSG, Garbay JR, Gehl J et al (2006) Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4:3-13 (Pubitemid 44755131)
26. Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, Kotaka M, Ruedl C (2010) Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol 184(9):4625-4629
27. Mir LM, Glass LF, Sersa G et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77(12):2336-2342 (Pubitemid 28263963)
28. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C (1991) Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27(1):68-72
29. Mir LM, Orlowski S, Poddevin B, Belehradek J Jr (1992) Electrochemotherapy tumor treatment is improved by interleukin- 2 stimulation of the host's defenses. Eur Cytokine Netw 3(3):331-334
30. Mir LM, Roth C, Orlowski S et al (1992) Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. CR Acad Sci III 314(12):539-544
31. Möller MG, Salwa S, Soden DM, O'Sullivan GC (2009) Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 9(11):1611-1630
32. Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925-931
33. Quaglino P, Mortera C, Osella-Abate S et al (2008) Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 15(8):2215-2222
34. Quaglino P, Osella-Abate S, Marenco F, Nardò T, Gado C, Novelli M, Savoia P, Bernengo MG (2011) FoxP3 expression on melanoma cells is related to early visceral spreading in melanoma patients treated by electrochemotherapy. Pigment Cell Melanoma Res 24(4):734-736
35. Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Peterson B, Seigler H, Pruitt SK, Tyler DS (2011) Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 213(2):306-316
36. Reinhold U (2011) Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies. Anticancer Drugs 22(8):711-718
37. Rigel DS (2010) Epidemiology of melanoma. Semin Cutan Med Surg 29(4):204-209
38. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roché H, Teissié J (2000) Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 10(5):468-474
39. Roux S, Bernat C, Al-Sakere B et al (2008) Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57(9):1291-1300
40. Rudolf Z, Stabuc B, Cemazr M et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29:229-235
41. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z (2000) Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 10(4):381-385
42. Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D (1997) Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett 116(1):85-92 (Pubitemid 27226154)
43. Sersa G, Cemazar M, Rudolf Z (2003) Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther 1:133-142
44. Sersa G, Miklavcic D, Cemazar M et al (1997) Electrochemothrapy with CDDP on LPB sarcoma: comparison of the antitumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochem Bioenerg 43:279-283 (Pubitemid 27465761)
45. Schadendorf D, Vaubel J, Livingstone E, Zimmer L (2012) Advances and perspectives in immunotherapy of melanoma. Ann Oncol 23(Suppl 10):x104-x108
46. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB (2000) Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 164(12):6230-6236 (Pubitemid 30408802)
47. Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109(3):270-274
48. Spagnolo F, Queirolo P (2012) Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 304(3):177-184
49. Testori A, Faries MB, Thompson JF et al (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104(4):391-396
50. Testori A, Tosti G, Martinoli C et al (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23(6):651-661
51. Triozzi PL, Tuthill RJ, Borden E (2011) Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy 3(5):653-671
52. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 1291:1-13
53. Crisan M, Crisan D, Sannino G, Lupsor M, Badea R, Amzica F (2013) Ultrasonographic staging of cutaneous malignant tumors: an ultrasonographic depth index. Arch Dermatol Res 305:305-313
54. Mamalis A, Garcha M, Jagdeo J (2014) Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res. doi: 10.1007/s00403-014-1457-7
55. Ruksha T, Aksenenko M, Papadopoulos V (2012) Role of translocator protein in melanoma growth and progression. Arch Dermatol Res 304:839-845